Search - Archive ouverte HAL Access content directly

Filter your results

15 Results
Structure: Internal structure identifier : 300123

Chromosomal abnormalities are major prognostic factors in elderly patients with multiple myeloma: the intergroupe francophone du myélome experience

Hervé Avet-Loiseau , Cyrille Hulin , Loic Campion , Philippe Rodon , Gerald Marit et al.
Journal of Clinical Oncology, 2013, 31 (22), pp.2806--2809. ⟨10.1200/JCO.2012.46.2598⟩
Journal articles hal-01064339v1
Image document

Addition of Androgens Improves Survival in Elderly Patients With Acute Myeloid Leukemia: A GOELAMS Study

Arnaud Pigneux , Marie C Béné , Philippe Guardiola , Christian C Recher , Jean-Francois Hamel et al.
Journal of Clinical Oncology, 2017, 35 (4), pp.387-393. ⟨10.1200/JCO.2016.67.6213⟩
Journal articles inserm-01480651v1
Image document

Detection of Anti-Pentraxin-3 Autoantibodies in ANCA-Associated Vasculitis

Amélie Simon , Jean-François Subra , Philippe Guilpain , Pascale Jeannin , Pascale Pignon et al.
PLoS ONE, 2016, 11 (1), pp.e0147091. ⟨10.1371/journal.pone.0147091⟩
Journal articles inserm-01273293v1
Image document

Impact of azacitidine before allogeneic stem-cell transplantation for myelodysplastic syndromes: a study by the Société Française de Greffe de Moelle et de Thérapie-Cellulaire and the Groupe-Francophone des Myélodysplasies.

Gandhi Damaj , Alain Duhamel , Marie Robin , Yves Beguin , Mauricette Michallet et al.
Journal of Clinical Oncology, 2012, 30 (36), pp.4533-40. ⟨10.1200/JCO.2012.44.3499⟩
Journal articles inserm-00821506v1

Results from a prospective, open-label, phase II trial of bendamustine in refractory or relapsed T-cell lymphomas: the BENTLY trial.

Gandhi Damaj , Rémy Gressin , Krimo Bouabdallah , Guillaume Cartron , Bachra Choufi et al.
Journal of Clinical Oncology, 2013, 31 (1), pp.104-10. ⟨10.1200/JCO.2012.43.7285⟩
Journal articles inserm-00868869v1

Microscopic polyangiitis and non-HBV polyarteritis nodosa with poor-prognosis factors: 10-year results of the prospective CHUSPAN trial.

Marc Ruivard , Maxime Samson , Xavier Puechal , Luc Mouthon , Hervé Devilliers et al.
Clinical and experimental rheumatology, 1970, pp.176-184
Journal articles hal-01656765v1
Image document

Shifting the Balance of Activating and Inhibitory Natural Killer Receptor Ligands on BRAF V600E Melanoma Lines with Vemurafenib

Alexandra Frazao , Marina Colombo , Emmanuelle Fourmentraux-Neves , Meriem Messaoudene , Sylvie Rusakiewicz et al.
Cancer Immunology Research, 2017, 5 (7), pp.582 - 593. ⟨10.1158/2326-6066.CIR-16-0380⟩
Journal articles inserm-01637027v1
Image document

Cell-of-Origin (COO) Classification, BCL2 and MYC Expression Associated Outcome in Younger Patients Treated By RCHOP Front-Line Therapy Versus Intensive Regimen Followed By Autologous Transplant for De Novo Advanced Diffuse Large B Cell Lymphoma (DLBCL) : Results of the French Prospective Multicenter Randomized Trial Goelams-075

Gaëlle Laboure , Marie-Cecile Parrens , Anjarasoa Tsaranazy , Magali Bordier , Steven Le Gouill et al.
55th Annual Meeting and Exposition of the American-Society-of-Hematology, Dec 2013, La Nouvelle Orléans, United States. 126 (23), pp.3920, 2015
Conference poster hal-01290432v1

Core-binding factor acute myeloid leukemia in first relapse: a retrospective study from the French AML Intergroup

A. Hospital , T. Prebet , S. Bertoli , X. Thomas , E. Tavernier et al.
Blood, 2014, 124 (8), pp.1312 - 1319. ⟨10.1182/blood-2014-01-549212⟩
Journal articles hal-01688071v1

Molecular classification and prognosis in younger adults with acute myeloid leukemia and intermediate-risk cytogenetics treated or not by gemtuzumab ozogamycin: Final results of the GOELAMS/FILO acute myeloid leukemia 2006-intermediate-risk trial

Anne Bouvier , Jean-Francois Hamel , Jacques Delaunay , Eric Delabesse , Pierre-Yves Dumas et al.
European Journal of Haematology, 2021, 107 (1), pp.111-121. ⟨10.1111/ejh.13626⟩
Journal articles hal-03604930v1

Long-acting recombinant coagulation factor IX albumin fusion protein (rIX-FP) in hemophilia B: results of a phase 3 trial

P. Saiag , R. Gutzmer , P. Ascierto , M. Maio , J.-J. Grob et al.
Blood, 2016, 127 (14), pp.1761-1769
Journal articles hal-02043874v1
Image document

Unique Functional Status of Natural Killer Cells in Metastatic Stage IV Melanoma Patients and Its Modulation by Chemotherapy

Giulia Fregni , Aurélie Perier , Gianfranco Pittari , Simon Jacobelli , Xavier Sastre et al.
Clinical Cancer Research, 2011, 17 (9), pp.2628-2637. ⟨10.1158/1078-0432.CCR-10-2084⟩
Journal articles inserm-03349277v1
Image document

Delineating FOXG1 syndrome

Nancy Vegas , Mara Cavallin , Camille Maillard , Nathalie Boddaert , Joseph Toulouse et al.
Neurology Genetics, 2018, 4 (6), pp.e281. ⟨10.1212/NXG.0000000000000281⟩
Journal articles hal-01920261v1

Prognostic impact of day 15 blast clearance in risk-adapted remission induction chemotherapy for younger patients with acute myeloid leukemia: long term results of the multicenter prospective LAM-2001 trial by the GOELAMS study group.

Sarah Bertoli , Pierre Bories , Marie C Béné , Sylvie Daliphard , Bruno Lioure et al.
Haematologica, 2013, epub ahead of print. ⟨10.3324/haematol.2013.091819⟩
Journal articles hal-00854975v1

Sequential mutational evaluation of CALR ‐mutated myeloproliferative neoplasms with thrombocytosis reveals an association between CALR allele burden evolution and disease progression

Laurane Cottin , Jeremie Riou , Corentin Orvain , Jean Christophe Ianotto , Françoise Boyer et al.
British Journal of Haematology, 2019, Epub ahead of print. ⟨10.1111/bjh.16276⟩
Journal articles inserm-02467617v1